Altimmune vs InflaRx
ALT and IFRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALT and IFRX compare
InflaRx scores higher on the StockData Score (5 against 4 for Altimmune), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALT | IFRX |
|---|---|---|
| Size and price | ||
| Market cap | $320M | – |
| Share price | $1.65 | $1.17 |
| Change, 1 year | −61.1% | −19.9% |
| Change, 5 years | −84.4% | −75.4% |
| Beta (5Y) | 1.07 | 1.47 |
| Employees | 13 | – |
| StockData Score | ||
| Total score | 4 | 5 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.7× | – |
| FCF yield | −32.0% | – |
| Growth | ||
| Revenue growth (TTM) | – | −82.3% |
| Revenue growth, 5Y average | −65.3% | – |
| Profitability | ||
| Gross margin | – | −24678% |
| Return on equity | −33.2% | – |
| Return on invested capital | −89.7% | – |
| Financial health | ||
| Debt / equity | 0.08 (better) | 0.00 |
| Interest coverage | −27.6× | – |
| Current ratio | 23.93 (better) | 4.13 |
| Altman Z-score | 1.51 | – |
| Piotroski F-score | 4 | – |
| Dividends and buybacks | ||
| Buyback yield | −22.1% | – |
| Shareholder yield | −22.1% | – |
| Ownership | ||
| Held by institutions | 77.9% | 135% |
| Held by insiders | 0.51% | 6.0% |
| Insider net buying, 12 months | $370K | – |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 21.8% | – |
Go deeper
- ALT stock overview
- ALT income statement
- ALT valuation and score
- IFRX stock overview
- IFRX income statement
- IFRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.